Advances in the treatment of acute myeloid leukemia: new drugs and new challenges
NJ Short, M Konopleva, TM Kadia, G Borthakur… - Cancer discovery, 2020 - AACR
The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …
the past few years, driven largely by translational research into its genomic landscape and …
New strategies to treat AML: novel insights into AML survival pathways and combination therapies
R Nair, A Salinas-Illarena, HM Baldauf - Leukemia, 2021 - nature.com
The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the
immense heterogeneity of this disease, treating it using a “one size fits all” approach is …
immense heterogeneity of this disease, treating it using a “one size fits all” approach is …
[HTML][HTML] Recent advances in the understanding and treatment of acute myeloid leukemia
J Watts, S Nimer - F1000Research, 2018 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …
Recent drug approvals for acute myeloid leukemia
C Lai, K Doucette, K Norsworthy - Journal of hematology & oncology, 2019 - Springer
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …
incidence that increases with age, and a generally poor prognosis. The disease is clinically …
Precision therapy for acute myeloid leukemia
X Yang, J Wang - Journal of hematology & oncology, 2018 - Springer
Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease.
Despite advances in understanding the pathogenesis of AML, the standard therapy …
Despite advances in understanding the pathogenesis of AML, the standard therapy …
Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
Advances in targeted therapy for acute myeloid leukaemia
S Kayser, MJ Levis - British journal of haematology, 2018 - Wiley Online Library
In the past few years, research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
Advances in acute myeloid leukemia
LF Newell, RJ Cook - Bmj, 2021 - bmj.com
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …
historically high mortality rates. The standard of care treatment remained unchanged for …
Emerging agents and regimens for AML
H Liu - Journal of hematology & oncology, 2021 - Springer
Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
[HTML][HTML] New drugs in acute myeloid leukemia
TM Kadia, F Ravandi, J Cortes, H Kantarjian - Annals of Oncology, 2016 - Elsevier
The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for
the past four decades. Improvements in supportive care and modifications to the dose and …
the past four decades. Improvements in supportive care and modifications to the dose and …